Galantamine Tablet, Film Coated
Product Images NDC 24979-722

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Galantamine (NDC 24979-722). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Upsher-smith Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

12mg-label (12mg Label)

The label for Galantamine Tablets USP, 12 mg, film coated tablets by Upsher-Smith Laboratories, LLC. The label includes product name, dosage strength (12 mg), package size (60 tablets), barcode, and manufacturing information. It states the active ingredient as galantamine hydrobromide equivalent to 12 mg galantamine per tablet, along with storage instructions and dispensing guidelines.*

FDA Label Image

4mg-label (4mg Label)

Label for Galantamine Tablets USP 4 mg film-coated tablets by Upsher-Smith Laboratories, LLC. The label indicates a quantity of 60 tablets with storage instructions and manufacturer information. It includes the NDC number 24979-722-04 and states the product is prescription only.*

FDA Label Image

8mg-label (8mg Label)

Galantamine Tablets USP 8 mg film-coated tablets in a package containing 60 tablets. Label includes NDC 24979-723-04 and indicates prescription use only. Manufactured by TWi Pharmaceuticals, with storage instructions and caution to keep out of reach of children. Dispensed in a tight, light-resistant container.*

FDA Label Image

Chemical Structure (Galantamine 01)

Chemical structure diagram of galantamine hydrobromide showing its molecular framework with labeled atoms including oxygen, nitrogen, and hydroxyl groups in a multi-ring system.*

FDA Label Image

Image Description (Galantamine 02)

A line graph depicting the mean change from baseline in ADAS-cog score over 21 weeks of treatment for placebo and galantamine doses of 8 mg/day, 16 mg/day, and 24 mg/day. The y-axis shows improvement versus decline, while the x-axis shows weeks of treatment with data points and error bars for each group.*

FDA Label Image

Image Description (Galantamine 04)

A bar chart depicting the percentage of patients across various CIBIC-plus rating categories, including markedly improved, moderately improved, minimally improved, no change, minimally worse, moderately worse, and markedly worse. Different bars compare groups treated with placebo and galantamine at dosages of 8 mg/day, 16 mg/day, and 24 mg/day.*

FDA Label Image

Image Description (Galantamine 05)

Line graph showing the mean change from baseline in ADAS-Cog score over 26 weeks of treatment. The x-axis represents weeks of treatment, and the y-axis represents change in score, with improvement and decline regions marked. The graph compares placebo, 24 mg/day, and 32 mg/day dosage groups, illustrating cognitive improvement trends over time.*

FDA Label Image

Image Description (Galantamine 06)

A cumulative percentage of patients chart showing ADAS-cog change from baseline on the x-axis and cumulative percentage of patients on the y-axis. Three groups are compared: Placebo, 24 mg/day, and 32 mg/day, with curves indicating greater cognitive improvement for higher doses.*

FDA Label Image

Image Description (Galantamine 07)

A bar chart depicting the percentage of patients categorized by CIBIC-plus rating levels ranging from markedly improved to markedly worse. Data are shown for three groups: placebo, 24 mg/day, and 32 mg/day doses, illustrating differences in patient outcomes across these treatment conditions.*

FDA Label Image

Image Description (Galantamine 08)

Line graph showing the mean change from baseline in ADAS-Cog score over 26 weeks of treatment. The graph compares placebo with two treatment groups receiving 24 mg/day and 32 mg/day doses. The y-axis ranges from decline to improvement, illustrating cognitive changes during the study period.*

FDA Label Image

Image Description (Galantamine 09)

A cumulative percentage of patients graph showing ADAS-cog change from baseline on the x-axis and cumulative percentage on the y-axis. The graph compares three groups: placebo, 24 mg/day galantamine, and 32 mg/day galantamine, illustrating patient response over a range of scores from -15 to +15.*

FDA Label Image

Image Description (Galantamine 10)

A bar chart illustrating CIBIC-plus Rating distributions for patients under three conditions: placebo, 24 mg/day, and 32 mg/day galantamine treatment. The x-axis categorizes ratings from markedly improved to markedly worse, and the y-axis shows the percentage of patients in each category.*

FDA Label Image

Image Description (Galantamine 11)

A line graph displaying mean change from baseline in ADAS-cog score over 13 weeks of treatment, comparing placebo and 24 or 32 mg/day galantamine. The y-axis shows improvement and decline, while the x-axis indicates weeks of treatment, illustrating the treatment effect over time.*

FDA Label Image

Image Description (Galantamine 12)

A cumulative percentage of patients line graph comparing ADAS-cog change from baseline between placebo and 24 or 32 mg/day dosage groups. The x-axis shows ADAS-cog change from baseline, ranging from -15 to 15, with markers for -10, -7, -4 points, and no change; the y-axis represents the cumulative percentage of patients from 0 to 100%. The graph includes two curves, one for placebo and one for 24 or 32 mg/day doses.*

FDA Label Image

Image Description (Galantamine 13)

Bar chart showing the distribution of patient outcomes based on the CIBIC-plus rating for placebo versus 24 or 32 mg/day treatment groups. The x-axis categorizes patient improvement levels from markedly improved to markedly worse, and the y-axis represents the percentage of patients.*

FDA Label Image

Figure2 (Galantamine03)

A cumulative percentage graph showing ADAS-cog change from baseline among patients for placebo and galantamine dosages of 8 mg/day, 16 mg/day, and 24 mg/day. The x-axis represents ADAS-cog changes, ranging from -15 to +15, and the y-axis shows the cumulative percentage of patients, from 0 to 100%. Four vertical reference lines mark -10, -7, 4 points, and no change.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.